Release and uptake of volatile organic compounds by human hepatocellular carcinoma cells (HepG2) in vitro

Cancer Cell International

Volumn 13, Issue 1, 2013, Pages

  Mochalski, Paweł ^a   Sponring, Andreas ^a,b   King, Julian ^a   Unterkofler, Karl ^a,c   Troppmair, Jakob ^b   Amann, Anton ^a,b  

^a ERICH SCHMID INSTITUTE OF MATERIALS SCIENCE   (Austria)

^b INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^c VORARLBERG UNIVERSITY OF APPLIED SCIENCES   (Austria)

Author keywords

Biomarkers; Emission of metabolites; Enzymes expression; GC MS; HepG2 cells; VOCs; Volatile organic compounds

Indexed keywords

2 ETHYLACROLEIN; 2 HEPTANONE; 2 HEPTENE; 2 METHYL 1 (METHYLTHIO)PROPANE; 2 METHYL 2 PROPENAL; 2 METHYL 5 (METHYLTHIO)FURAN; 2 METHYL PROPANAL; 2 NONANONE; 2 PENTANONE; 3 HEPTANONE; 3 METHYL BUTANAL; 3 METHYL THIOPHENE; 3 OCTANONE; ALDEHYDE DERIVATIVE; ALPHA 2 MACROGLOBULIN; BENZALDEHYDE; DIMETHYL SULFIDE; ETHYL METHYL SULFIDE; ISOPRENE; ISOVALERALDEHYDE; KETONE DERIVATIVE; N BUTYL ACETATE; N HEXANAL; N PROPYL ACETATE; N PROPYL PROPIONATE; PLASMA PROTEIN; SULFUR DERIVATIVE; TRANSFERRIN; UNCLASSIFIED DRUG; VOLATILE ORGANIC COMPOUND;

ADOLESCENT; ARTICLE; BIOCHEMISTRY; CANCER CELL CULTURE; COMPARATIVE STUDY; ENZYME ACTIVITY; GAS CHROMATOGRAPHY; GLASS BOTTLE; HUMAN; HUMAN CELL; IN VITRO STUDY; LIMIT OF DETECTION; LIMIT OF QUANTITATION; LIVER CELL CARCINOMA; MALE; MASS SPECTROMETRY; MEASUREMENT;

EID: 84880183201     PISSN: None     EISSN: 14752867     Source Type: Journal    
DOI: 10.1186/1475-2867-13-72     Document Type: Article

References (56)

1. Amann A, Poupart G, Telser S, Ledochowski M, Schmid A, Mechtcheriakov S. Applications of breath gas analysis in medicine. Int J Mass Spectrometry 2004, 239:227-233.
2. Amann A, Smith D. Breath analysis for clinical diagnosis and therapeutic monitoring 2005, New Jersey: World Scientific.
3. Erhart S, Amann A, Haberlandt E, Edlinger G, Schmid A, Filipiak W, Schwarz K, Mochalski P, Rostasy K, Karall D, et al. 3-Heptanone as a potential new marker for valproic acid therapy. J Breath Res 2009, 3(1):016004. 10.1088/1752-7155/3/1/016004, 21383452.
4. Miekisch W, Schubert JK, Noeldge-Schomburg GF. Diagnostic potential of breath analysis-focus on volatile organic compounds. Clin Chim Acta 2004, 347(1-2):25-39.
5. Filipiak W, Sponring A, Filipiak A, Baur M, Ager C, Wiesenhofer H, Margesin R, Nagl M, Troppmair J, Amann A. Volatile Organic Compounds (VOCs) Released by athogenic Microorganisms in Vitro: Potential Breath Biomarkers for Early-Stage Diagnosis of Disease. Volatile Biomarkers: Non-Invasive Diagnosis in Physiology and Medicine 2013, SD: Elsevier, Amann A.
6. Bajtarevic A, Ager C, Pienz M, Klieber M, Schwarz K, Ligor M, Ligor T, Filipiak W, Denz H, Fiegl M, et al. Noninvasive detection of lung cancer by analysis of exhaled breath. BMC Cancer 2009, 9:348. 10.1186/1471-2407-9-348, 2761408, 19788722.
7. Phillips M, Altorki N, Austin JH, Cameron RB, Cataneo RN, Kloss R, Maxfield RA, Munawar MI, Pass HI, Rashid A, et al. Detection of lung cancer using weighted digital analysis of breath biomarkers. Clin Chim Acta 2008, 393(2):76-84. 10.1016/j.cca.2008.02.021, 2497457, 18420034.
8. Poli D, Carbognani P, Corradi M, Goldoni M, Acampa O, Balbi B, Bianchi L, Rusca M, Mutti A. Exhaled volatile organic compounds in patients with non-small cell lung cancer: cross sectional and nested short-term follow-up study. Respir Res 2005, 6:71. 10.1186/1465-9921-6-71, 1185565, 16018807.
9. Wehinger A, Schmid A, Mechtcheriakov S, Ledochowski M, Grabmer C, Gastl GA, Amann A. Lung cancer detection by proton transfer reaction mass-spectrometric analysis of human breath gas. Int J Mass Spectrom 2007, 265(1):49-59.
10. Kanoh S, Kobayashi H, Motoyoshi K. Exhaled ethane: an in vivo biomarker of lipid peroxidation in interstitial lung diseases. Chest 2005, 128(4):2387-2392. 10.1378/chest.128.4.2387, 16236899.
11. Scholpp J, Schubert JK, Miekisch W, Geiger K. Breath markers and soluble lipid peroxidation markers in critically ill patients. Clin Chem Lab Med 2002, 40(6):587-594.
12. Filipiak W, Sponring A, Filipiak A, Ager C, Schubert J, Miekisch W, Amann A, Troppmair J. TD-GC-MS analysis of volatile metabolites of human lung cancer and normal cells in vitro. Cancer Epidemiol. Biomarkers Prev. 2010, 19(1):182-195. 10.1158/1055-9965.EPI-09-0162, 20056637.
13. Filipiak W, Sponring A, Mikoviny T, Ager C, Schubert J, Miekisch W, Amann A, Troppmair J. Release of volatile organic compounds (VOCs) from the lung cancer cell line CALU-1 in vitro. Cancer Cell Int 2008, 8:17. 10.1186/1475-2867-8-17, 2639533, 19025629.
14. Hanai Y, Shimono K, Oka H, Baba Y, Yamazaki K, Beauchamp GK. Analysis of volatile organic compounds released from human lung cancer cells and from the urine of tumor-bearing mice. Cancer Cell Int 2012, 12(1):7. 10.1186/1475-2867-12-7, 3312856, 22364569.
15. Sponring A, Filipiak W, Ager C, Schubert J, Miekisch W, Amann A, Troppmair J. Analysis of volatile organic compounds (VOCs) in the headspace of NCI-H1666 lung cancer cells. Cancer Biomark 2010, 7(3):153-161.
16. Sponring A, Filipiak W, Mikoviny T, Ager C, Schubert J, Miekisch W, Amann A, Troppmair J. Release of volatile organic compounds from the lung cancer cell line NCI-H2087 in vitro. Anticancer Res 2009, 29(1):419-426.
17. Buszewski B, Ulanowska A, Ligor T, Jackowski M, Klodzinska E, Szeliga J. Identification of volatile organic compounds secreted from cancer tissues and bacterial cultures. J Chromatogr B Analyt Technol Biomed Life Sci 2008, 868(1-2):88-94.
18. Filipiak W, Sponring A, Baur MM, Ager C, Filipiak A, Wiesenhofer H, Nagl M, Troppmair J, Amann A. Characterization of volatile metabolites taken up by or released from Streptococcus pneumoniae and Haemophilus influenzae by using GC-MS. Microbiology 2012, 158(Pt 12):3044-3053.
19. Filipiak W, Sponring A, Baur MM, Filipiak A, Ager C, Wiesenhofer H, Nagl M, Troppmair J, Amann A. Molecular analysis of volatile metabolites released specifically by Staphylococcus aureus and Pseudomonas aeruginosa. BMC Microbiol 2012, 12:113. 10.1186/1471-2180-12-113, 3444334, 22716902.
20. Castaneda F, Zimmermann D, Nolte J, Baumbach JI. Role of undecan-2-one on ethanol-induced apoptosis in HepG2 cells. Cell Biol Toxicol 2007, 23(6):477-485. 10.1007/s10565-007-9009-y, 17453350.
21. Huber W. Basic calculations about the limit of detection and its optimal determination. Accred Qual Assur 2003, 8:213-217.
22. Crabb DW, Matsumoto M, Chang D, You M. Overview of the role of alcohol dehydrogenase and aldehyde dehydrogenase and their variants in the genesis of alcohol-related pathology. Proc Nutr Soc 2004, 63(1):49-63. 10.1079/PNS2003327, 15099407.
23. Ditlow CC, Holmquist B, Morelock MM, Vallee BL. Physical and enzymatic properties of a class II alcohol dehydrogenase isozyme of human liver: pi-ADH. Biochemistry 1984, 23(26):6363-6368. 10.1021/bi00321a012, 6397223.
24. Klyosov AA. Kinetics and specificity of human liver aldehyde dehydrogenases toward aliphatic, aromatic, and fused polycyclic aldehydes. Biochemistry 1996, 35(14):4457-4467. 10.1021/bi9521102, 8605195.
25. Wagner FW, Pares X, Holmquist B, Vallee BL. Physical and enzymatic properties of a class III isozyme of human liver alcohol dehydrogenase: chi-ADH. Biochemistry 1984, 23(10):2193-2199. 10.1021/bi00305a014, 6375718.
26. Ma S, Chan KW, Lee TK, Tang KH, Wo JY, Zheng BJ, Guan XY. Aldehyde dehydrogenase discriminates the CD133 liver cancer stem cell populations. Molecular cancer research : MCR 2008, 6(7):1146-1153. 10.1158/1541-7786.MCR-08-0035, 18644979.
27. Imai T. Human carboxylesterase isozymes: catalytic properties and rational drug design. Drug Metab Pharmacokinet 2006, 21(3):173-185. 10.2133/dmpk.21.173, 16858120.
28. Del Monte M, Citti L, Gervasi PG. Isoprene metabolism by liver microsomal mono-oxygenases. Xenobiotica 1985, 15(7):591-597. 10.3109/00498258509045888, 4049899.
29. Watson WP, Cottrell L, Zhang D, Golding BT. Metabolism and molecular toxicology of isoprene. Chem Biol Interact 2001, 135-136:223-238.
30. Bogaards JJ, Freidig AP, van Bladeren PJ. Prediction of isoprene diepoxide levels in vivo in mouse, rat and man using enzyme kinetic data in vitro and physiologically-based pharmacokinetic modelling. Chem Biol Interact 2001, 138(3):247-265. 10.1016/S0009-2797(01)00276-9, 11714482.
31. Small RD, Golding BT, Watson WP. Species differences in the stereochemistry of the metabolism of isoprene in vitro. Xenobiotica 1997, 27(11):1155-1164. 10.1080/004982597239912, 9413919.
32. Miekisch W, Schubert JK, Vagts DA, Geiger K. Analysis of volatile disease markers in blood. Clin Chem 2001, 47(6):1053-1060.
33. Kushch I, Arendacka B, Stolc S, Mochalski P, Filipiak W, Schwarz K, Schwentner L, Schmid A, Dzien A, Lechleitner M, et al. Breath isoprene-aspects of normal physiology related to age, gender and cholesterol profile as determined in a proton transfer reaction mass spectrometry study. Clin Chem Lab Med 2008, 46(7):1011-1018.
34. Sharkey TD. Isoprene synthesis by plants and animals. Endeavour 1996, 20(2):74-78. 10.1016/0160-9327(96)10014-4, 8690002.
35. Silver GM, Fall R. Enzymatic synthesis of isoprene from dimethylallyl diphosphate in aspen leaf extracts. Plant Physiol 1991, 97(4):1588-1591. 10.1104/pp.97.4.1588, 1081206, 16668590.
36. McGrath LT, Patrick R, Silke B. Breath isoprene in patients with heart failure. Eur J Heart Fail 2001, 3(4):423-427. 10.1016/S1388-9842(01)00128-3, 11511427.
37. King J, Mochalski P, Unterkofler K, Teschl G, Klieber M, Stein M, Amann A, Baumann M. Breath isoprene: muscle dystrophy patients support the concept of a pool of isoprene in the periphery of the human body. Biochem Biophys Res Commun 2012, 423(3):526-530. 10.1016/j.bbrc.2012.05.159, 22683640.
38. Koc H, King J, Teschl G, Unterkofler K, Teschl S, Mochalski P, Hinterhuber H, Amann A. The role of mathematical modeling in VOC analysis using isoprene as a prototypic example. J Breath Res 2011, 5(3):037102. 10.1088/1752-7155/5/3/037102, 21654024.
39. King J, Mochalski P, Kupferthaler A, Unterkofler K, Koc H, Filipiak W, Teschl S, Hinterhuber H, Amann A. Dynamic profiles of volatile organic compounds in exhaled breath as determined by a coupled PTR-MS/GC-MS study. Physiol Meas 2010, 31(9):1169-1184. 10.1088/0967-3334/31/9/008, 20664160.
40. King J, Kupferthaler A, Unterkofler K, Koc H, Teschl S, Teschl G, Miekisch W, Schubert J, Hinterhuber H, Amann A. Isoprene and acetone concentration profiles during exercise on an ergometer. J Breath Res 2009, 3(2):027006. 10.1088/1752-7155/3/2/027006, 21383461.
41. King J, Koc H, Unterkofler K, Mochalski P, Kupferthaler A, Teschl G, Teschl S, Hinterhuber H, Amann A. Physiological modeling of isoprene dynamics in exhaled breath. J Theor Biol 2010, 267(4):626-637. 10.1016/j.jtbi.2010.09.028, 20869370.
42. King J, Kupferthaler A, Frauscher B, Hackner H, Unterkofler K, Teschl G, Hinterhuber H, Amann A, Hogl B. Measurement of endogenous acetone and isoprene in exhaled breath during sleep. Physiol Meas 2012, 33(3):413-428. 10.1088/0967-3334/33/3/413, 22370046.
43. Moreb JS, Zucali JR, Ostmark B, Benson NA. Heterogeneity of aldehyde dehydrogenase expression in lung cancer cell lines is revealed by Aldefluor flow cytometry-based assay. Cytometry B Clin Cytom 2007, 72(4):281-289.
44. Rutter AV, Chippendale TW, Yang Y, Spanel P, Smith D, Sule-Suso J. Quantification by SIFT-MS of acetaldehyde released by lung cells in a 3D model. Analyst 2013, 138(1):91-95. 10.1039/c2an36185j, 23136643.
45. Jelski W, Szmitkowski M. Alcohol dehydrogenase (ADH) and aldehyde dehydrogenase (ALDH) in the cancer diseases. Clin Chim Acta 2008, 395(1-2):1-5.
46. Burnell JC, Li TK, Bosron WF. Purification and steady-state kinetic characterization of human liver beta 3 beta 3 alcohol dehydrogenase. Biochemistry 1989, 28(17):6810-6815. 10.1021/bi00443a005, 2819035.
47. Kedishvili NY, Bosron WF, Stone CL, Hurley TD, Peggs CF, Thomasson HR, Popov KM, Carr LG, Edenberg HJ, Li TK. Expression and kinetic characterization of recombinant human stomach alcohol dehydrogenase. Active-site amino acid sequence explains substrate specificity compared with liver isozymes. J Biol Chem 1995, 270(8):3625-3630. 10.1074/jbc.270.8.3625, 7876099.
48. Jelski W, Zalewski B, Szmitkowski M. Alcohol dehydrogenase (ADH) isoenzymes and aldehyde dehydrogenase (ALDH) activity in the sera of patients with liver cancer. J Clin Lab Anal 2008, 22(3):204-209. 10.1002/jcla.20241, 18484658.
49. Walker V, Mills GA. Urine 4-heptanone: a beta-oxidation product of 2-ethylhexanoic acid from plasticisers. Clin Chim Acta 2001, 306(1-2):51-61.
50. Tangerman A. Measurement and biological significance of the volatile sulfur compounds hydrogen sulfide, methanethiol and dimethyl sulfide in various biological matrices. J Chromatogr B Analyt Technol Biomed Life Sci 2009, 877(28):3366-3377. 10.1016/j.jchromb.2009.05.026, 19505855.
51. Glauser TA, Kerremans AL, Weinshilboum RM, 2 1992. Drug Metab Dispos 1992, 20:247-255. 2.
52. Weisiger RA, Jakoby WB. Thiol S-methyltransferase from rat liver. Arch Biochem Biophys 1979, 196(2):631-637. 10.1016/0003-9861(79)90317-5, 485170.
53. Reitman ZJ, Parsons DW, Yan H. IDH1 and IDH2: not your typical oncogenes. Cancer Cell 2010, 17(3):215-216. 10.1016/j.ccr.2010.02.024, 20227034.
54. Filipiak W, Filipiak A, Ager C, Wiesenhofer H, Amann A. Optimization of sampling parameters for collection and preconcentration of alveolar air by needle traps. J Breath Res 2012, 6(2):027107. 10.1088/1752-7155/6/2/027107, 22621839.
55. Gong Y, Eom IY, Lou DW, Hein D, Pawliszyn J. Development and application of a needle trap device for time-weighted average diffusive sampling. Anal Chem 2008, 80(19):7275-7282. 10.1021/ac800884f, 18763805.
56. Mieth M, Kischkel S, Schubert JK, Hein D, Miekisch W. Multibed needle trap devices for on site sampling and preconcentration of volatile breath biomarkers. Anal Chem 2009, 81(14):5851-5857. 10.1021/ac9009269, 19548667.